Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3.
Chowdhury
S
S
Division of Transplantation, MCP Hahnemann University, Philadelphia, PA, USA.
Kode
R K
RK
Ranganna
K
K
Damask
A M
AM
Lam
A
A
Fyfe
B
B
Stabler
S
S
Kumar
A M
AM
Tomeny
M B
MB
Kumar
M S
MS
Pankewycz
O
O
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D016572:Cyclosporine / Q000008:administration & dosage*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011993:Recombinant Fusion Proteins; D008776:Methylprednisolone Hemisuccinate; D016572:Cyclosporine; D000077552:Basiliximab; D009173:Mycophenolic Acid